China
· Delayed Price · Currency is CNY Shanghai RAAS Blood Products Statistics
Total Valuation
Shanghai RAAS Blood Products has a market cap or net worth of CNY 47.16 billion. The enterprise value is 43.81 billion.
| Market Cap | 47.16B |
| Enterprise Value | 43.81B |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | Sep 30, 2024 |
Share Statistics
Shanghai RAAS Blood Products has 6.60 billion shares outstanding. The number of shares has decreased by -1.25% in one year.
| Shares Outstanding | 6.60B |
| Shares Change (YoY) | -1.25% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 27.22% |
| Float | 4.39B |
Valuation Ratios
The trailing PE ratio is 26.63 and the forward PE ratio is 19.83.
| PE Ratio | 26.63 |
| Forward PE | 19.83 |
| PS Ratio | 5.70 |
| PB Ratio | 1.54 |
| P/FCF Ratio | 157.72 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.73, with an EV/FCF ratio of 146.54.
| EV / Earnings | 24.60 |
| EV / Sales | 5.27 |
| EV / EBITDA | 17.73 |
| EV / EBIT | 19.18 |
| EV / FCF | 146.54 |
Financial Position
The company has a current ratio of 5.19, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.19 |
| Quick Ratio | 2.84 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.01 |
| Interest Coverage | 21,796.70 |
Financial Efficiency
Return on equity (ROE) is 5.82% and return on invested capital (ROIC) is 4.67%.
| Return on Equity (ROE) | 5.82% |
| Return on Assets (ROA) | 4.42% |
| Return on Capital (ROIC) | 4.67% |
| Revenue Per Employee | 2.56M |
| Profits Per Employee | 547,411 |
| Employee Count | 3,254 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 1.46 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.41% in the last 52 weeks. The beta is 0.49, so Shanghai RAAS Blood Products's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +7.41% |
| 50-Day Moving Average | 7.30 |
| 200-Day Moving Average | 7.33 |
| Relative Strength Index (RSI) | 48.89 |
| Average Volume (20 Days) | 51,200,382 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Shanghai RAAS Blood Products had revenue of CNY 8.32 billion and earned 1.78 billion in profits. Earnings per share was 0.27.
| Revenue | 8.32B |
| Gross Profit | 3.30B |
| Operating Income | 2.28B |
| Pretax Income | 2.22B |
| Net Income | 1.78B |
| EBITDA | 2.47B |
| EBIT | 2.28B |
| Earnings Per Share (EPS) | 0.27 |
Balance Sheet
The company has 3.36 billion in cash and 1.54 million in debt, giving a net cash position of 3.36 billion or 0.51 per share.
| Cash & Cash Equivalents | 3.36B |
| Total Debt | 1.54M |
| Net Cash | 3.36B |
| Net Cash Per Share | 0.51 |
| Equity (Book Value) | 30.76B |
| Book Value Per Share | 4.64 |
| Working Capital | 6.62B |
Cash Flow
In the last 12 months, operating cash flow was 796.89 million and capital expenditures -497.90 million, giving a free cash flow of 298.99 million.
| Operating Cash Flow | 796.89M |
| Capital Expenditures | -497.90M |
| Free Cash Flow | 298.99M |
| FCF Per Share | 0.05 |
Margins
Gross margin is 39.71%, with operating and profit margins of 27.47% and 21.42%.
| Gross Margin | 39.71% |
| Operating Margin | 27.47% |
| Pretax Margin | 26.68% |
| Profit Margin | 21.42% |
| EBITDA Margin | 29.72% |
| EBIT Margin | 27.47% |
| FCF Margin | 3.60% |
Dividends & Yields
This stock pays an annual dividend of 0.04, which amounts to a dividend yield of 0.50%.
| Dividend Per Share | 0.04 |
| Dividend Yield | 0.50% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 3 |
| Payout Ratio | 13.88% |
| Buyback Yield | 1.25% |
| Shareholder Yield | 1.75% |
| Earnings Yield | 3.76% |
| FCF Yield | 0.63% |
Stock Splits
The last stock split was on September 28, 2016. It was a forward split with a ratio of 1.8.
| Last Split Date | Sep 28, 2016 |
| Split Type | Forward |
| Split Ratio | 1.8 |
Scores
Shanghai RAAS Blood Products has an Altman Z-Score of 19.19.
| Altman Z-Score | 19.19 |
| Piotroski F-Score | n/a |